1. Home
  2. DRH vs RARE Comparison

DRH vs RARE Comparison

Compare DRH & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamondrock Hospitality Company

DRH

Diamondrock Hospitality Company

HOLD

Current Price

$12.02

Market Cap

2.5B

Sector

Real Estate

ML Signal

HOLD

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$32.19

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRH
RARE
Founded
2004
2010
Country
United States
United States
Employees
35
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.7B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
DRH
RARE
Price
$12.02
$32.19
Analyst Decision
Buy
Strong Buy
Analyst Count
10
20
Target Price
$10.38
$59.10
AVG Volume (30 Days)
2.3M
3.0M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
3.51%
N/A
EPS Growth
N/A
7.31
EPS
N/A
N/A
Revenue
N/A
$673,000,000.00
Revenue This Year
$3.44
$13.12
Revenue Next Year
$2.42
$37.80
P/E Ratio
$38.41
N/A
Revenue Growth
N/A
20.13
52 Week Low
$7.45
$18.29
52 Week High
$12.54
$39.89

Technical Indicators

Market Signals
Indicator
DRH
RARE
Relative Strength Index (RSI) 56.33 59.44
Support Level $9.10 $31.82
Resistance Level $12.54 $34.01
Average True Range (ATR) 0.28 1.74
MACD -0.08 -0.04
Stochastic Oscillator 45.88 42.73

Price Performance

Historical Comparison
DRH
RARE

About DRH Diamondrock Hospitality Company

Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: